INFERGEN Drug Profile

Summary for Tradename: INFERGEN

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for INFERGEN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for INFERGEN Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2011-12-13	Company disclosures
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2002-05-06	Company disclosures
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2039-03-29	Company disclosures

3) Low Certainty: US Patents for INFERGEN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2039-02-26	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2037-01-11	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2034-02-05	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2033-08-01	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2034-02-05	Patent claims search
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663		2029-01-29	Patent claims search

International Patents for INFERGEN

Country	Patent Number	Estimated Expiration
Spain	2128348
Ireland	913656
China	1064018
Israel	99778
European Patent Office	0911033
European Patent Office	0422697

Supplementary Protection Certificates for INFERGEN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SZ 17/1999	Austria		PRODUCT NAME: INTERFERON ALFACON-1
99C0024	Belgium		PRODUCT NAME: INTERFERON ALFACON-1; REGISTRATION NO/DATE: EU/1/98/O87/001 19990201
SPC/GB99/017	United Kingdom

INFERGEN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: INFERGEN

Introduction to Interferons and INFERGEN

Interferons are a class of biologic drugs that play a crucial role in the immune system by helping to fight off infections and diseases. INFERGEN, specifically, is an interferon alfacon-1, used primarily in the treatment of chronic hepatitis C and, in some cases, for other viral infections.

Global Interferons Market Overview

The global interferons market is projected to grow significantly over the coming years. Here are some key points:

• Market Size and Growth: The interferons market is estimated to reach USD 10.15 billion in 2024 and is expected to grow at a CAGR of 3.91% to reach USD 12.30 billion by 2029[1][4].
• Regional Dominance: North America currently holds the largest market share, but the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period[1].

Drivers of Market Growth

Several factors are driving the growth of the interferons market:

Increased Drug Approvals

The growing number of approvals for interferon-based treatments by regulatory bodies such as the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Research Authority (HRA) is a significant driver. For example, the approval of novel formulations like SNG001, an interferon-beta-1a inhalation formulation, boosts market growth[4].

High Strategic Collaborations

Major players in the market are engaging in strategic collaborations, licensing agreements, and research partnerships to expand their product portfolios and improve distribution networks. For instance, the collaboration between Bayer and Curadev to develop STING antagonists for auto-inflammatory diseases is a notable example[4].

Increased Research and Developments

The rising prevalence of diseases such as cancer, hepatitis, and multiple sclerosis creates opportunities for pharmaceutical companies to develop and market interferon biosimilars. Increased investments in R&D and technological advancements are key contributors to market growth[4].

Rising Healthcare Awareness

Growing health awareness among the population leads to increased demand for effective treatments, including interferons. Innovative launches in medications for various diseases further propel market growth[4].

Challenges and Restraints

Despite the growth drivers, there are several challenges that the interferons market faces:

Lack of Skilled Professionals

The lack of trained professionals with knowledge of interferon treatment methods can curb market growth. This shortage can affect the proper administration and monitoring of interferon therapies[4].

High Cost

Interferon treatments are often expensive, which can limit accessibility for patients. The high cost of these therapies, sometimes exceeding tens of thousands of dollars annually, is a significant restraint[4].

Financial Trajectory of Interferons Market

The financial performance of the interferons market is closely tied to the overall pharmaceutical industry trends:

• Revenue Projections: The market is expected to grow from USD 10.15 billion in 2024 to USD 12.30 billion by 2029, indicating a steady increase in revenue[1].
• Key Players: Companies like Merck & Co., Inc., Biogen Inc, Bayer AG, Amega Biotech, and F. Hoffmann-La Roche Ltd are major players in the interferons market. Their financial performance and strategic moves significantly impact the market's overall trajectory[1].

Impact of Pharmaceutical R&D Trends

The broader pharmaceutical R&D landscape also influences the interferons market:

• Declining ROI in R&D: The return on investment (ROI) for pharmaceutical R&D has been declining, which could impact long-term sustainability. However, strategic investments in areas with high unmet medical needs, such as oncology and chronic diseases, continue to drive innovation[3].
• Precision Medicine: Advances in precision medicine, including genomic sequencing and molecular profiling, are enhancing the efficacy and safety of biologic treatments like interferons. This trend is expected to continue, driving further innovation in the field[3].

Case Study: Dupixent and Biologic Success

The success of biologics like Dupixent, which targets interleukin-4 and interleukin-13 and has generated over $8 billion in annual revenue, highlights the revenue potential of biologic drugs. This success story underscores the market's willingness to invest in and adopt effective biologic therapies, despite their high costs[3].

Regional Growth and Market Share

• Asia-Pacific Growth: This region is expected to grow at the highest CAGR during the forecast period, driven by increasing healthcare awareness and investments in R&D[1].
• North America Dominance: Currently, North America holds the largest market share due to advanced healthcare infrastructure and high adoption rates of biologic therapies[1].

Key Takeaways

• The interferons market is projected to grow steadily, driven by increased drug approvals, strategic collaborations, and rising healthcare awareness.
• Challenges such as the lack of skilled professionals and high treatment costs need to be addressed.
• The market's financial trajectory is influenced by key players and broader pharmaceutical R&D trends.
• Advances in precision medicine are expected to enhance the efficacy and safety of interferon treatments.

FAQs

1. What is the current size of the global interferons market? The global interferons market size is estimated to reach USD 10.15 billion in 2024[1].

2. Who are the major players in the interferons market? Major players include Merck & Co., Inc., Biogen Inc, Bayer AG, Amega Biotech, and F. Hoffmann-La Roche Ltd[1].

3. What is the fastest-growing region in the interferons market? The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period[1].

4. What are the main drivers of growth in the interferons market? Key drivers include increased drug approvals, strategic collaborations, rising healthcare awareness, and growing research and development activities[4].

5. What are the major challenges facing the interferons market? The lack of skilled professionals and the high cost of treatments are significant challenges[4].

Sources:

1. Mordor Intelligence: Interferons Market Analysis | Industry Forecast, Size & Report ...
2. Globenewswire: Infinera Corporation Reports Preliminary First Quarter 2024 Financial Results
3. DrugBank Blog: Investment Trends in Pharmaceutical Research
4. Data Bridge Market Research: Global Interferons Market – Industry Trends and Forecast to 2029